Bill Wexler's Dog Pound Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound

REFR 1.940

-7.6%

Nov 25 3:39 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Trocchi who wrote (3135)	8/18/1999 11:43:00 PM
From: BDR	Read Replies (1) of 10293

I would like to know exactly which patent it is that covers GBC 590. I read some of the patents and saw that Dr. Platt did not assign them to IGG (the subsidiary of SAFS) but only licensed them, one for only until 2002. If that one was for GBC 590 that would be just long enough for studies (paid for by the shareholders of SAFS) to give Platt some idea how effective the drug was. If it looked like he had a winner he would then control the revenue stream that would result and the shareholders would/could be cut out. Any longs factoring that possibility into their valuation models?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next